NTLA Q1 2025 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-42.5% YoY

Gross Profit

$17M100.0% margin

Operating Income

-$121M-726.6% margin

Net Income

-$114M-687.6% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

+29.2%

Cash Flow

Operating Cash Flow

-$149M

Free Cash Flow

-$150M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$986M

Total Liabilities

$206M

Stockholders' Equity

$780M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$29M	-42.5%
Gross Profit	$17M	$26M	-37.1%
Operating Income	-$121M	-$114M	-6.0%
Net Income	-$114M	-$107M	-6.4%